The presence of cytopenia has been linked to a higher risk of progression to acute myeloid leukemia (AML) and lower overall survival rates in patients with myelofibrosis, as revealed by a recent real-world study. This highlights the critical importance of considering cytopenia when determining treatment strategies for myelofibrosis patients. Further research is necessary to explore how targeting anemia or low platelet levels may influence the risk of AML progression, overall survival outcomes, and the likelihood of undergoing a stem cell transplant.
Lead study author, Dr. Lindey Rein, emphasizes the significance of identifying risk factors for poor prognoses and tailoring treatment approaches for myelofibrosis patients who are not eligible for transplant. With 70% of myelofibrosis patients being cytopenic at diagnosis, the study findings underscore the need for personalized and targeted therapeutic interventions in this patient population. The data also revealed disparities in survival rates and AML progression probabilities between cytopenic and non-cytopenic patients, indicating the potential impact of cytopenia on disease outcomes.
Read more from curetoday.com